These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20187322)

  • 1. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.
    Comen EA; Robson M
    Oncology (Williston Park); 2010 Jan; 24(1):55-62. PubMed ID: 20187322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
    Comen EA; Robson M
    Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of PARP inhibitors for metastatic breast cancer.
    Irshad S; Ashworth A; Tutt A
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1243-51. PubMed ID: 21916578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
    Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
    Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.
    Annunziata CM; O'Shaughnessy J
    Clin Cancer Res; 2010 Sep; 16(18):4517-26. PubMed ID: 20823142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research progresses of the PARP inhibitors for the treatment of cancer].
    He YJ; Liu RH; Ning CQ; Yu NF
    Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
    Sandhu SK; Yap TA; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducing synthetic lethality using PARP inhibitors.
    Boss DS; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.